Regulation of Prescription Drugs & Biologics by the U.S. Food & Drug Administration
2.0
creditsAverage Course Rating
Reviews FDA’s regulation of prescription drugs and biologics. Discusses the relevant parts of the Food Drug & Cosmetic Act and FDA’s regulations. Includes the development of drugs and biologics from preclinical studies to investigational new drug status to post-approval (‘Phase IV’) studies. Discusses generic drugs, orphan drugs, and biosimilars. Examines ‘market exclusivity.’ Explores the public debate on ‘compassionate use’ of unapproved drugs and biologics. Introduces whether FDA should continue to withhold from public disclosure clinical data submitted to support the approval of drugs and biologics.
No Course Evaluations found